Form 8-K - Current report:
SEC Accession No. 0001140361-25-008919
Filing Date
2025-03-17
Accepted
2025-03-17 08:20:57
Documents
15
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20045600_8k.htm   iXBRL 8-K 30215
2 EXHIBIT 99.1 ef20045600_ex99-1.htm EX-99.1 166956
6 image00006.jpg GRAPHIC 2266
  Complete submission text file 0001140361-25-008919.txt   353069

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20250317.xsd EX-101.SCH 3973
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20250317_lab.xml EX-101.LAB 22690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20250317_pre.xml EX-101.PRE 16546
18 EXTRACTED XBRL INSTANCE DOCUMENT ef20045600_8k_htm.xml XML 4213
Mailing Address WALLSTRASSE 16 BERLIN 2M 10179
Business Address WALLSTRASSE 16 BERLIN 2M 10179 49 89 2153 9035
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 25742467
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)